Identification of the Antigens Recognised by Colorectal Cancer Patients Using Sera from Patients Who Exhibit a Crohn's-like Lymphoid Reaction.
SEREX
colon cancer
crohn’s-like lymphoid reaction (CLR)
immunoglobulin heavy chain
immunotherapy
Journal
Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414
Informations de publication
Date de publication:
29 07 2022
29 07 2022
Historique:
received:
18
06
2022
revised:
21
07
2022
accepted:
25
07
2022
entrez:
26
8
2022
pubmed:
27
8
2022
medline:
30
8
2022
Statut:
epublish
Résumé
A Crohn’s-like lymphoid reaction (CLR) is observed in about 15% of colorectal cancer (CRC) patients and is associated with favourable outcomes. To identify the immune targets recognised by CRC CLR patient sera, we immunoscreened a testes cDNA library with sera from three patients. Immunoscreening of the 18 antigens identified by SEREX with sera from normal donors showed that only the heavy chain of IgG3 (IGHG3) and a novel antigen we named UOB-COL-7, were solely recognised by sera from CRC CLR patients. ELISA showed an elevation in IgG3 levels in patients with CRC (p = 0.01). To extend our studies we analysed the expression of our SEREX-identified antigens using the RNA-sequencing dataset (GSE5206). We found that the transcript levels of multiple IGHG probesets were highly significant (p < 0.001) in their association with clinical features of CRC while above median levels of DAPK1 (p = 0.005) and below median levels of GTF2H5 (p = 0.004) and SH3RF2 (p = 0.02) were associated with improved overall survival. Our findings demonstrate the potential of SEREX-identified CRC CLR antigens to act as biomarkers for CRC and provide a rationale for their further characterization and validation.
Identifiants
pubmed: 36008952
pii: biom12081058
doi: 10.3390/biom12081058
pmc: PMC9406176
pii:
doi:
Substances chimiques
Carrier Proteins
0
Immunoglobulin G
0
Oncogene Proteins
0
SH3RF2 protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Déclaration de conflit d'intérêts
The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Références
Br J Cancer. 2021 Apr;124(8):1411-1420
pubmed: 33558709
Tumour Biol. 2014 Jun;35(6):6011-20
pubmed: 24659425
Methods Mol Med. 2005;115:109-28
pubmed: 15998965
Int J Biochem Cell Biol. 2004 Nov;36(11):2250-7
pubmed: 15313470
Oncodev Biol Med. 1981;2(5):355-66
pubmed: 7329817
Cancer Res. 1976 Dec;36(12):4562-9
pubmed: 1000501
Am J Gastroenterol. 2000 Dec;95(12):3607-14
pubmed: 11151900
Methods Mol Med. 2005;109:403-8
pubmed: 15585934
Toxicol Sci. 2011 Jun;121(2):245-56
pubmed: 21447608
Biochem Biophys Res Commun. 2005 Jul 22;333(1):206-15
pubmed: 15950191
Hum Vaccin Immunother. 2014;10(2):358-9
pubmed: 24231833
Oncotarget. 2015 Nov 24;6(37):40081-94
pubmed: 26472025
FASEB J. 2007 Sep;21(11):2931-8
pubmed: 17475920
J Clin Pathol. 2016 Jun;69(6):497-504
pubmed: 26519488
Genes Chromosomes Cancer. 2015 May;54(5):288-302
pubmed: 25706801
Sci Rep. 2019 Mar 14;9(1):4484
pubmed: 30872752
Mod Pathol. 1990 May;3(3):332-5
pubmed: 2362940
Cancer Lett. 2018 Aug 28;430:148-159
pubmed: 29778566
Cancer Manag Res. 2019 Mar 07;11:2073-2085
pubmed: 30881131
Front Immunol. 2019 Aug 22;10:1884
pubmed: 31507584
Cancer Causes Control. 2014 Nov;25(11):1513-21
pubmed: 25225034
PLoS One. 2012;7(11):e47362
pubmed: 23133595
Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-12
pubmed: 35658496
Int J Oncol. 2005 Jan;26(1):247-58
pubmed: 15586247
BMC Med Genomics. 2013 Sep 04;6:28
pubmed: 24007313
Mol Med Rep. 2014 Sep;10(3):1205-14
pubmed: 25017204
BMC Med Genomics. 2011 Jun 07;4:49
pubmed: 21649900
Am J Transl Res. 2020 Nov 15;12(11):7002-7019
pubmed: 33312347
Braz J Med Biol Res. 2010 Dec;43(12):1225-31
pubmed: 21103787
Dis Colon Rectum. 2010 Jan;53(1):31-8
pubmed: 20010347
FEBS Lett. 2009 Dec 17;583(24):3966-73
pubmed: 19850042
Mol Cell Proteomics. 2015 Nov;14(11):2988-99
pubmed: 26351264
Genome Biol. 2007;8(7):R131
pubmed: 17615082
Methods Mol Biol. 2007;377:203-22
pubmed: 17634619
Biochem Biophys Res Commun. 2005 Oct 7;335(4):1293-304
pubmed: 16112646
Nat Rev Gastroenterol Hepatol. 2019 Jun;16(6):361-375
pubmed: 30886395
Mol Immunol. 2007 Mar;44(9):2221-7
pubmed: 17174398
Prostate. 2013 May;73(6):614-23
pubmed: 23060098
Anticancer Res. 2021 Apr;41(4):1871-1882
pubmed: 33813392
PLoS One. 2013 Aug 19;8(8):e72458
pubmed: 23977302
Cancer Res. 2003 Oct 1;63(19):6488-95
pubmed: 14559841
Autoimmunity. 2005 Mar;38(2):123-37
pubmed: 16040333
Biomed Pharmacother. 2018 Mar;99:645-654
pubmed: 29653487
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Feb;22(1):30-4
pubmed: 24598646
Cancer Immun. 2012;12:8
pubmed: 22896753
Br J Cancer. 2002 Jun 5;86(11):1817-23
pubmed: 12087472
Cell Death Dis. 2013 Dec 05;4:e945
pubmed: 24309932
Apoptosis. 2014 Feb;19(2):371-86
pubmed: 24305735
PLoS Comput Biol. 2009 Dec;5(12):e1000598
pubmed: 20011106
Cell Death Dis. 2019 Nov 26;10(12):895
pubmed: 31772156
Nature. 2012 Jul 18;487(7407):330-7
pubmed: 22810696
World J Gastrointest Oncol. 2019 Mar 15;11(3):195-207
pubmed: 30918593
Cancer Res. 2002 Dec 1;62(23):7042-9
pubmed: 12460925
Genome Biol. 2003;4(10):231
pubmed: 14519192
Transfusion. 1961 Jan-Feb;1:5-8
pubmed: 13758692
PLoS One. 2014 May 22;9(5):e97359
pubmed: 24853685
CA Cancer J Clin. 2017 Mar;67(2):93-99
pubmed: 28094848
Saudi Med J. 2008 Apr;29(4):507-13
pubmed: 18382789
Cancers (Basel). 2019 Oct 09;11(10):
pubmed: 31601052
Oncotarget. 2015 Nov 3;6(34):36774-88
pubmed: 26405175
Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11810-3
pubmed: 8524854
Nan Fang Yi Ke Da Xue Xue Bao. 2017 Mar 20;37(3):407-410
pubmed: 28377362
Carcinogenesis. 2014 Mar;35(3):624-34
pubmed: 24130170
Hum Mol Genet. 2001 Mar 1;10(5):445-56
pubmed: 11181568
Gastroenterology. 2010 Mar;138(3):958-68
pubmed: 19914252
PLoS One. 2013 Jul 31;8(7):e70332
pubmed: 23936189
Exp Oncol. 2011 Jun;33(2):94-8
pubmed: 21716206